AI assistant
CAMBIUM BIO LIMITED — Board/Management Information 2020
Jun 3, 2020
64666_rns_2020-06-03_d49950a6-4f4d-4769-abe3-6abd9d08dfcc.pdf
Board/Management Information
Open in viewerOpens in your device viewer
==> picture [160 x 33] intentionally omitted <==
ASX Announcement
4 June 2020
Regeneus board change
Regeneus Ltd (ASX: RGS) ( Regeneus or the Company ), a clinical-stage regenerative medicine company, today announced that non-executive director Dr Glen Richards has resigned to allow him to focus on his other commitments.
Dr Richards joined the board of Regeneus as non-executive director in April 2015.
Regeneus’ Independent Chairman Barry Sechos, thanked Dr Richards for his contribution.
“The Board would like to thank Glen for his tremendous efforts and deep business knowledge during his tenure as a Director. He has been an asset to Regeneus and we wish him all the best,” said Mr Sechos.
-ENDS-
About Regeneus
Regeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies to address unmet medical needs in human health markets with a focus on neuropathic pain, including osteoarthritis and various skin conditions, with its platform technologies Progenza and Sygenus. Visit www.regeneus.com.au for more information.
Authorisation & Additional information
This announcement was authorised by the Board of Directors of Regeneus Ltd
Investor and Media Contact
WE Communications T: 02 9237 2805 E: [email protected]
2 Paddington Street, Paddington, NSW 2021 Ph: +61 2 9499 8010 • www.regeneus.com.au • ABN 13 127 035 358